Choosing the right pharmacotherapy for non-Hodgkin’s lymphoma: does one size fit all?
Sign Up to like & getrecommendations! Published in 2019 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2019.1582643
Abstract: Diffuse large B-cell lymphoma (DLBCL), the most common subtype of aggressive B-cell non-Hodgkin’s lymphoma (NHL), is highly curable with conventional chemoimmunotherapy. Indolent B-cell lymphomas (... read more here.
Keywords: hodgkin lymphoma; pharmacotherapy non; choosing right; right pharmacotherapy ... See more keywords